2003, Number 2
<< Back Next >>
Acta Med 2003; 1 (2)
A specific antineoplastic agent. The case of chronic granulocytic leukaemia
Benítez BL
Language: Spanish
References: 9
Page: 109-110
PDF size: 34.04 Kb.
Text Extraction
No abstract
REFERENCES
Faderl S, Talpaz M, Estrow Z, O’Brien S, Kurzrock R, Kantarjan HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172.
Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre ove a 16-year period. Br J Haematol 1997; 96: 111-116.
Savage DG, Antman KH. Imatinib mesylate-A new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
Druker BJ, Sawyer CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042. (Erratum, N Engl J Med 2001;345:232.)
Kantarjian H, Sawyers Ch, Hochhaus A, Guilhot F, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
O’Brien SG, Guilhot F, Larson RA, Gathmann I, et al,. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423.
Full text